MARLBOROUGH, Mass. — May 16, 2013 – Advanced Cell Technology, Inc.(“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, today confirmed that the vision of a patient enrolled in a clinical investigation of the company’s retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs) has improved from 20/400 to 20/40 following treatment. The improvement was first reported on May 15, 2013, in a news article published by Reuters.
“We continue to be encouraged by the progress we see in our ongoing clinical investigations, though the results included in the article were confidential and not intended for publication at that time,” commented Gary Rabin, chairman and CEO of ACT. “Our plan is still to publish additional results from the clinical investigations when we have a significant aggregation of data.”
ACT is currently enrolling patients in three clinical trials in the U.S. and Europe for treatment of Stargardt’s macular dystrophy (SMD) and dry age-related macular degeneration (dry AMD) with hESC-derived RPE cells. These trials are prospective, open-label studies, designed to determine the safety and tolerability of hESC-derived RPE cells following sub-retinal transplantation into patients with dry AMD or SMD at 12 months, the study’s primary endpoint.
ACT cautions that the improvement in the patient’s vision reported in this press release may not be indicative of future results of clinical trials of the RPE cells derived from hESCs. The information included in this press release should be considered in the context of ACT’s filings with the U.S. Securities and Exchange Commission, including the risk factors included in our most recent annual report on Form 10-K and quarterly report on Form 10-Q.
This is huge but the stock market is being controlled by traders...we have no control. Institutional buying only will change things in the long run..I hope. Good luck..just keep accumulating if you really believe in this company...or trade it like almost everyone is doing.